Trials / Completed
CompletedNCT01473563
A Study of Home Administration of Pemetrexed as Maintenance Treatment for Advanced Nonsquamous Non-Small Cell Lung Cancer (NSCLC)
Home Delivery of Pemetrexed as Maintenance Treatment in Patients Who Have Not Progressed After Induction Therapy for Advanced Nonsquamous Nonsmall Cell Lung Cancer: A Feasibility Study
- Status
- Completed
- Phase
- Phase 2
- Study type
- Interventional
- Enrollment
- 52 (actual)
- Sponsor
- Eli Lilly and Company · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
The main purpose for this study is to answer the following research questions: * Can pemetrexed be administered safely at the participant's home, using the same treatment procedure as in a hospital setting? * Will the participant be satisfied with home care? * How might this impact the participant's quality of life? * What are the required medical resources needed to give pemetrexed in a home setting?
Conditions
- Nonsquamous Non-Small Cell Neoplasm of Lung
- Non-Small Cell Lung Cancer Metastatic
- Non-Small Cell Lung Cancer Stage IIIB
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | Pemetrexed | Administered intravenously |
Timeline
- Start date
- 2011-12-01
- Primary completion
- 2013-09-01
- Completion
- 2013-09-01
- First posted
- 2011-11-17
- Last updated
- 2014-10-06
- Results posted
- 2014-10-06
Locations
9 sites across 2 countries: Sweden, United Kingdom
Source: ClinicalTrials.gov record NCT01473563. Inclusion in this directory is not an endorsement.